article12 September 2024 | By Catherine Eckford (European Pharmaceutical Review), Dr Alaa Hamed (Sanofi)
In this article, Dr Alaa Hamed, Global Head of Medical Affairs for Rare Disease at Sanofi, shares why the company’s enzyme replacement therapy Xenpozyme® (olipudase alfa) has promise for the rare genetic disease acid sphingomyelinase deficiency (ASMD).